Cabot Shareholders Back Board Nominees and Governance Measures

The latest announcement is out from Cabot ( (CBT) ).

On March 12, 2026, Cabot held its annual meeting of stockholders, at which shareholders elected all of the board’s nominees—Sean D. Keohane, Raffiq Nathoo, and Thierry Vanlancker—to the director class whose terms will expire in 2029, while the terms of six other incumbent directors continued unchanged. The meeting also saw strong advisory approval of compensation for the company’s named executive officers and ratified Deloitte & Touche LLP as Cabot’s independent registered public accounting firm for the fiscal year ending September 30, 2026, signaling broad shareholder support for current governance, pay practices, and audit oversight.

The most recent analyst rating on (CBT) stock is a Buy with a $77.00 price target. To see the full list of analyst forecasts on Cabot stock, see the CBT Stock Forecast page.

Spark’s Take on CBT Stock

According to Spark, TipRanks’ AI Analyst, CBT is a Outperform.

CBT scores well on solid financial quality (healthy margins, improved leverage, strong free cash flow) and supportive valuation (moderate P/E plus dividend). The score is held back by mixed earnings-call operating outlook—material weakness and pricing pressure in Reinforcement Materials despite cost actions—and technically the stock is strong but near overbought.

To see Spark’s full report on CBT stock, click here.

More about Cabot

Cabot is a specialty chemicals company that develops and manufactures performance materials for industrial customers worldwide. Its portfolio typically includes reinforcing carbons, specialty carbons, and other advanced materials used in sectors such as transportation, infrastructure, energy, and consumer products, with a focus on enhancing performance and efficiency for its customers.

Average Trading Volume: 480,137

Technical Sentiment Signal: Sell

Current Market Cap: $3.58B

See more data about CBT stock on TipRanks’ Stock Analysis page.